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Abstract
Background: Hyperinsulinemic hypoglycemia is relatively recently recognized in persons undergoing bariatric
surgery although knowledge and experience with this condition may not be commensurate with the number of
such procedures being performed globally. This paper presents a novel case as an example of how such patients
may present and how they may be investigated.
Case Presentation: A 69-year-old man was assessed 3 months post-fundoplication surgery for postprandial
hypoglycaemia with neuroglycopenia that became progressively severe. A 72-h fast failed to show hypoglycaemia.
During a clinic visit, the patient became confused and had a low plasma glucose, high plasma insulin, and high
plasma C-peptide; symptoms were relieved with glucose. No tumours were visualized on CT, MRI, or endoscopic
ultrasound. A total body Indium111-octreotide scan was negative. Selective arterial calcium stimulation showed a
high insulin gradient in the splenic and superior mesenteric arteries, suggesting diffuse pancreatic beta cell
hyperplasia. The patient declined pancreatic resection and recurrent symptomatic hypoglycaemia was successfully
prevented with low dose octreotide.
Conclusions: Although increasingly recognized following bariatric surgery, this is the first reported development of
NIPHS (non-insulinoma pancreatogenous hypoglycemia syndrome) following fundoplication surgery, as well as the
first documented use of octreotide in post-operative NIPHS. Medical management may be an alternative to surgery
for patients with this rare condition.
Background
It is common to see patients presenting with symptoms
attributed to “hypoglycaemia” in endocrinology and gen-
eral medicine clinics. The first step in evaluation requires
documentation that hypoglycaemia is in fact present and
the cause of the symptoms. Once hypoglycaemia is pro-
ven, the next step is to determine whether it is mediated
by insulin or by an alternate disease process. Most insulin-
mediated hypoglycaemia is due to either exogenous insulin
use or the presence of an insulinoma but in recent years,
the differential diagnosis has expanded to include other
forms of beta cell dysfunction, some of which may simu-
late insulinoma, as illustrated in the following case.
Case presentation
A 69-year-old non-obese man (BMI 25.2 kg/m2) pre-
sented with a 3 month history of progressive symptoms
of hypoglycaemia following meals. He noted that symp-
toms first appeared 14 years ago at which time a formal
72 hour fast failed to show any hypoglycaemia. How-
ever, his symptoms had become dramatically worse 2
months after undergoing a recent Nissan fundoplication
surgery to repair a paraesophageal hiatus hernia. The
episodes were characterized by agitation, sweatiness,
rapid heart rate, tremor, light headedness, confusion and
cognitive changes likened to alcohol intoxication that
occurred an hour or two after meals. One such episode
had resulted in loss of consciousness and subsequent
involvement in a motor vehicle crash. There were no
nocturnal symptoms and no history of weight loss,
abdominal pain or diarrhoea. He denied the use of oral
hypoglycaemic agents or insulin.
Initial investigations were performed during his first
clinical visit when the patient was noticed to become
diaphoretic and confused during the history and physi-
cal examination. The onset of these symptoms occurred
at approximately 1.5 hours after breakfast. Plasma
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glucose was 0.8 mmol/L, serum ketones were negative,
serum insulin 445.6 pmol/L and serum C-peptide of
3.54 nmol/L - values > 18 pmol/L (insulin) and >0.2
nmol/L(Cpeptide) are indicative of hyperinsulinemic
hypoglycaemia. The confusion was completely relieved
by oral glucose.
Computed tomography of the abdomen showed no
focal abnormalities of the pancreas. Abdominal MRI
showed good visualization of the pancreas with no dila-
tation of pancreatic ducts or focal enhancing masses in
the pancreas or peripancreatic regions. Endoscopic
ultrasound was negative, as was total body Indium111-
octreotide scan.
Selective arterial catheterization and calcium stimula-
tion testing was performed (Figure 1) with results
shown in Table 1. The presence of a high calcium-sti-
mulated insulin gradient in arteries supplying the body
and tail of the pancreas suggested diffuse b-cell hyper-
plasia and a diagnosis of noninsulinoma pancreatogen-
ous hypoglycaemia syndrome (NIPHS). The patient
declined subtotal pancreatic resection and was success-
fully treated with Sandostatin 50 ug subcutaneously




syndrome (NIPHS) was first described by Service et al.
in 5 adults with symptoms of postprandial neuroglyco-
penia secondary to hyperinsulinemic hypoglycaemia.
Diagnostic criteria for NIPHS includes a positive Whip-
ple’s triad (typical symptoms occurring in the setting of
documented hypoglycaemia, relieved by glucose admin-
istration) following a mixed meal, a negative 72-h fast,
negative peri-operative imaging studies for insulinoma,
positive arterial calcium stimulation test, and islet hyper-
trophy or nesidioblastosis in pancreatic tissue [1]. This
differs with the presentation of an insulinoma in that
insulinomas are classically associated with fasting hyper-
insulinemic hypoglycaemia and are usually identifiable
on peri- or intraoperative imaging studies [2]. Diffuse
calcium-stimulated hyperinsulinism from multiple seg-
ments of pancreatic vascular supply help to differentiate
NIPHS from a solitary tiny insulinoma [3]. Furthermore,
the neuroglycopenic symptoms of NIPHS distinguish it
from “reactive” hypoglycaemia and the dumping syn-
drome sometimes seen in patients post-gastric bypass
surgery [2,4]. No patients with NIPHS have been identi-
fied as having mutations in the Kir6.2 or SUR1 genes as
Figure 1 Schematic diagram of intra-arterial calcium stimulated selective hepatic venous sampling for determination of segmental
hyperinsulinemic response.
Table 1 Insulin levels in right hepatic vein before and after sequential selective arterial catheterization and intra-
arterial calcium infusion
Sampling distribution Pre-infusion hepatic vein
insulin (mIU/ml)




Splenic artery 3.9 62 15-fold
Gastroduodenal artery 5.1 5.4 No change
Superior mesenteric artery 6.8 31 4-fold
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occurs in certain children with a syndrome of familial
hyperinsulinemic hypoglycaemia; however, the two
groups do share similar histologic findings within the
pancreas, namely, nesidioblastosis - a histologic diagno-
sis consisting of widespread b-cell hyperplasia along
with diffuse proliferation and hypertrophy of islet cells
from pancreatic ducts [1,2,5-7]. Recently, trophic factors
and modulators of pancreatic morphology such as gluca-
gon-like peptide 1 (GLP1) and islet neogenesis-asso-
ciated protein (INGAP) have been implicated in the
proposed pathologic changes leading to nesidioblastosis
following upper gastrointestinal surgery [4,6,8-10]. To
date, subtotal esophagectomy, subtotal gastrectomy,
roux-en-Y gastric bypass, Billroth I partial gastrectomy,
and Billroth II gastric bypass surgeries have all been
associated with changes consistent with NIPHS, while
gastric banding procedures have been shown to induce
transient asymptomatic hyperinsulinemic hypoglycaemia
in select patients [4,6,8,11-13]. Whether the change in
gastrointestinal architecture contributes to the patho-
genesis of NIPHS or whether the consequent weight
loss and reduction of insulin resistance simply unmasks
a primary underlying condition is still a matter of some
debate [4,8,9]. In our patient’s case, the onset of hypo-
glycaemia after the fundoplication after 14 years of
quiescence suggests a causal or aggravating association
but further case series would be needed to confirm such
an association.
As it stands, gradient-guided surgical debulking is the
only definitive treatment for NIPHS with pancreatic
changes of nesidioblastosis [14]. While some have
achieved desirable results with limited pancreatic resec-
tion, others have suggested that near-total or total pan-
createctomy is the only definitive solution to this
condition - as is the case for infants with diffuse nesi-
dioblastosis and familial hyperinsulinemic hypoglycaemia
[11,12,15,16]. Pharmacologically, symptoms have been
shown to be adequately controlled with the use of diaz-
oxide[6]. However, diazoxide use is not without poten-
tial adverse effects including hypotension and severe
edema. Octreotide inhibits insulin secretion from both
benign and malignant insulinomas via its effect on the
G protein coupled somatostatin receptor [17]. Inhibition
of insulin secretion from otherwise normal beta cells sti-
mulated by sulfonylurea overdose demonstrates the abil-
ity of this drug to correct and prevent hypoglycaemia in
beta cell hyperfunction outside of the tumour setting
[18]. The present report confirms the utility of this
medication to successfully treat diffuse beta cell hyper-
function/hyperplasia as well.
With the rising incidence of gastric bypass surgeries, it
is important to be able to recognize the clinical picture
of NIPHS and to investigate accordingly. This is the first
description of the development of NIPHS following
fundoplication surgery. Although octreotide has been
successfully used to treat adult onset nesidioblastosis
before, this is the first report of its use in post operative
NIPHS [12].
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